In addition, treatment increased multiple immune-related gene sets in the tumor tissue of donor #1 group, including IFNγ-mediated signaling pathway, T-cell activation, MHC-II protein complex, DC differentiation, and Th1-type immune response (99). The gene discussed is IFNG; the disease is neoplasm.